SOURCE: MBio Diagnostics, Inc.
BOULDER, CO--(Marketwire - Jan 3, 2013) - MBio Diagnostics, Inc., a diagnostics company focused on enabling better healthcare decisions through immediate multi-disease diagnostics, today announced that Michael J. Lochhead, Ph.D., Vice President of MBio Diagnostics, will present a company overview at the Biotech Showcase, on Monday, January 7 at 2:30 p.m. PST at the Parc 55 Hotel in San Francisco, CA. The presentation will focus on MBio's near-term plans to commercialize the first in a pipeline of diagnostic products on a single platform developed to deliver comprehensive testing of multiple diseases from a single sample.
MBio Diagnostics, Inc. (www.mbiodx.com) is a privately held clinical diagnostics and life sciences technology company based in Boulder, CO. MBio is developing a suite of simple, multiplexed diagnostic tests using its proprietary LightDeck™ technology. Initial product development focuses on high impact infectious diseases, including HIV, hepatitis, and influenza. The company's product development is aimed at decentralized testing, from the clinic to the home.